Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
This study is currently recruiting participants.
Verified May 2012
by Amylin Pharmaceuticals, LLC.
Study NCT01144338 Information provided by Amylin Pharmaceuticals, LLC.
First Received on June 10, 2010. Last Updated on February 7, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 2 Diabetes Mellitus
Additional conditions recognized in this trial
Diabetes Mellitus, Type 2
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Interventions listed in this trial
Exenatide Once Weekly
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Physiological Effects of Drugs
Sponsors listed in this trial
Amylin Pharmaceuticals, LLC.
Eli Lilly and Company
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers